Fish Analysis, Chronic Lymphocytic Leukemia (CLL) Profile

Cytogenetics Test Requisition Specimen Information Billing Information Contact Us CPT Codes     Print Page


Pseudonyms: Chronic Lymphocytic Leukemia Panel, CLL Panel, B-cell CLL

TURNAROUND TIME: 7 to 10 days
Fluorescence in situ hybridization
  • Collect: 2 mL bone marrow aspirate in sodium heparin (green); 5 mL peripheral blood in sodium heparin (green) also acceptable
  • Minimum Collection: 1 mL bone marrow or 2 mL peripheral blood
  • Transport: bone marrow or peripheral blood in sodium heparin (green) at 20-25oC; specimen should arrive in the laboratory within 24 hours of collection
  • Stability: Ambient: 24 hours; Refrigerated: 24 hours; Frozen: unacceptable
  • Unacceptable Conditions: Frozen or clotted specimens; paraffin-embedded specimens; specimens in anticoagulants other than sodium heparin
A Cytogenetics Laboratory Test Requisition must accompany the specimen. Contact the Cytogenetics Laboratory
at 918-502-1722 to obtain further information.
Test Summary: Probes included: ATM, D12Z1, D13S319, LAMP1, TP53
Methods: A dual-color FISH analysis performed on interphase cells using a probe for the ATM gene on chromosome 11q22.3 and a probe for the TP53 gene on chromosome 17p13.1; analysis of 200 interphase cells.
A triple-color FISH analysis performed on interphase cells using probes for the chromosome 12 centromere (D12Z1), the D13S319 locus on chromosome 13q14 and the LAMP1 gene on chromosome 13q34; analysis of 200 interphase cells.
Interpretation: A positive result is reported when the percent of cells with an abnormality exceeds the normal reference range for the probes. The detection of an abnormal clone indicates a diagnosis of CLL with the specific chromosome abnormality. A negative result indicates no abnormality was observed but does not rule out the presence of a neoplastic disorder.
FDA Approval: This test is approved by the FDA for in vitro diagnostic testing
Indications for Use:
  • In patients with CLL, establishing the percentage of neoplastic cells at diagnosis
  • Identify patients with CLL who have deletions of ATM, TP53 and/or D13S319 and/or trisomy 12
  • Provide prognostic indicators for patients with CLL
  • Quantify disease after therapy